Clinical trial
A Phase 2/3, Adaptive, Randomized, Controlled, Double-blind Study to Investigate the Pharmacokinetics, Efficacy and Safety of the Hyperimmune Equine Serum (INM005) in Adult Patients With Moderate to Severe Confirmed SARS-CoV-2 Disease.
NCT04494984 is registered in ClinicalTrials.gov with Inmunova S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2/3, Adaptive, Randomized, Controlled, Double-blind Study to Investigate the Pharmacokinetics, Efficacy and Safety of the Hyperimmune Equine Serum (INM005) in Adult Patients With Moderate to Severe Confirmed SARS-CoV-2 Disease.
- Lead sponsor
- Inmunova S.A.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- July 27, 2020
- Completion date
- December 30, 2020
- Enrollment
- 243 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.